Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.
Tagliaferri P, Barile C, Caraglia M, Guarrasi R, Morelli D, Ricciardi B, Martignetti A, Librera MT, Matano E, Della Vecchia A, Catalano G, Famiani M, Palmieri G, Correale P, Bianco AR. Tagliaferri P, et al. Among authors: barile c. Am J Clin Oncol. 1998 Feb;21(1):48-53. doi: 10.1097/00000421-199802000-00011. Am J Clin Oncol. 1998. PMID: 9499257 Clinical Trial.
High-dose recombinant interleukin-2/verapamil combination in advanced cancer.
Tagliaferri P, Correale P, Mottola M, de Simone G, Montesarchio V, Matano E, Rea A, Morabito A, Famiani M, Ciardiello F, Tortora G, Caraglia M, Barile C, Palmieri G, Bianco AR. Tagliaferri P, et al. Among authors: barile c. Eur J Cancer. 1996 Jul;32A(8):1436-7. doi: 10.1016/0959-8049(96)00126-8. Eur J Cancer. 1996. PMID: 8869114 Free article. Clinical Trial. No abstract available.
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
Pasini F, Barile C, Caruso D, Modena Y, Fraccon AP, Bertolaso L, Menon D, La Russa F, Crepaldi G, Bononi A, Spezzano R, Padrini R, Corona G, Gusella M. Pasini F, et al. Among authors: barile c. Invest New Drugs. 2018 Oct;36(5):927-932. doi: 10.1007/s10637-018-0631-8. Epub 2018 Jun 28. Invest New Drugs. 2018. PMID: 29956056 Clinical Trial.
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, Fratino L, Gernone A, De Vivo R, Pappagallo GL, Galligioni E. Caffo O, et al. Among authors: barile c. Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284. Future Oncol. 2015. PMID: 25760977 Clinical Trial.
M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.
Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R. Rossi E, et al. Among authors: barile c. Clin Cancer Res. 2010 Nov 1;16(21):5233-43. doi: 10.1158/1078-0432.CCR-10-1449. Epub 2010 Oct 26. Clin Cancer Res. 2010. PMID: 20978147
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M, Pierantoni F, Bortolami A, Palleschi D, Zivi A, Nicodemo M, Sartori D, De Vivo R, Zustovich F, Bimbatti D, Pastorelli D, Vultaggio GD, Soraru' M, Ballestrin M, Modonesi C, Randisi P, Barile C, Perri G, Basso U, Zagonel V. Maruzzo M, et al. Among authors: barile c. Target Oncol. 2022 Jul;17(4):467-474. doi: 10.1007/s11523-022-00892-z. Epub 2022 Jun 25. Target Oncol. 2022. PMID: 35751733 Free PMC article.
Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A, Spezzano R, Telatin GA, Corona G, Padrini R. Gusella M, et al. Among authors: barile c. Cancer Chemother Pharmacol. 2019 Mar;83(3):493-500. doi: 10.1007/s00280-018-3751-0. Epub 2018 Dec 12. Cancer Chemother Pharmacol. 2019. PMID: 30542768
115 results